Interventional Cardiology News and Research

RSS

NC Quantum Apex PTCA Dilatation Balloon Catheter receives CE Mark and FDA approval

Boston Scientific Corporation today announced CE Mark and U.S. Food and Drug Administration approval of its NC Quantum Apex PTCA Dilatation Balloon Catheter. The Company plans to launch the product in European markets this week and in the U.S. next month.

25 May 2010

Volcano to highlight extensive pipeline of imaging and therapy products at EuroPCR 2010

Volcano Corporation announced today the company's plans to highlight its new product launches, presence in live cases, and participation in late breaking trials during EuroPCR from May 25 – 28 in Paris.

24 May 2010

PrimeWire PRESTIGE Pressure Guide Wire receives 510(k) clearance, CE Mark approval

Volcano Corporation announced today it received both 510(k) clearance and CE Mark approval for its PrimeWire PRESTIGE Pressure Guide Wire for use with patients who have both single-vessel and multi-vessel disease. This next generation pressure wire is compatible with Volcano's full suite of integrated multi-modality consoles and stand-alone physiology systems as well as various hemodynamic monitoring systems.

19 May 2010

Positive results from Cytori's Celution-based ADRC trial for treatment of no-option chronic heart disease patients

The first clinical trial of adipose (fat) tissue-derived stem and regenerative cells (ADRCs) for the treatment of no-option chronic heart disease patients showed the following: the procedure was safe and feasible; it demonstrated a statistically significant improvement in maximum oxygen consumption and patients' aerobic capacity measured as metabolic equivalents

10 May 2010

Cytori Therapeutics to initiate European medical device approval study for Celution System

The first clinical trial of adipose (fat) tissue-derived stem and regenerative cells for the treatment of heart attacks showed a substantial reduction in the size of injury to the heart, an improvement in the amount of blood supply to the heart muscle, and a corresponding functional improvement in the amount of blood the heart can pump.

7 May 2010

Xience V sales out-performing Promus in Japanese drug-eluting stent market: MRG

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, when Abbott Vascular's Xience V and Boston Scientific's Promus entered the Japanese drug-eluting stent market in Q1 2010, both companies picked up share from competitors Medtronic and Cordis.

6 May 2010

Volcano to distribute AngioSculpt PTCA Scoring Balloon Catheter in Japan

Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it has entered into a distribution agreement with AngioScore for its AngioSculpt® PTCA Scoring Balloon Catheter for coronary indications in Japan. This is the first of what Volcano believes will be many products distributed by Volcano Japan, which now includes more than 50 direct sales representatives.

28 Apr 2010

Tryton Medical widens European availability of Side Branch Stent System

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced the launch of the TRYTON Side Branch Stent™ System in Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom. The stent is used to treat bifurcation lesions, the largest unmet need confronting interventional cardiology.

23 Apr 2010

Magnetic targeting may enhance effectiveness of stem cell therapies for heart injuries

Researchers at the Cedars-Sinai Heart Institute have found in animals that infusing cardiac-derived stem cells with micro-size particles of iron and then using a magnet to guide those stem cells to the area of the heart damaged in a heart attack boosts the heart's retention of those cells and could increase the therapeutic benefit of stem cell therapy for heart disease.

9 Apr 2010

Svelte Medical Systems' Series A extension financing oversubscribed

Svelte Medical Systems, Inc. is pleased to announce that it has successfully completed the extension of its Series A financing from institutional and private investors including CNF Investments, Apjohn Ventures and the Fischell family. The company's Series A extension was oversubscribed and included an initial investment by Norwich Ventures LP. Norwich Ventures is a seed and early-stage venture capital firm committed to helping entrepreneurs, healthcare professionals and inventors build innovative medical technology companies.

9 Apr 2010

NewYork-Presbyterian Hospital installs high-tech imaging systems for heart and vascular surgeries

In a move that could change the way many patients undergo surgery, NewYork-Presbyterian Hospital has installed five state-of-the-art Siemens Artis zeego- medical imaging systems that provide faster, more accurate 3-D images of the body with a quality never before attainable.

3 Apr 2010

Drilling technology used to reopen arteries

Then Wilks was referred to Dr. Fred Leya, an interventional cardiologist at Loyola University Health System. Leya used a device similar to a dental drill to reopen three arteries that had turned as hard as bone.

25 Mar 2010

Medtronic' Endeavor DES demonstrates safety and efficacy profile for coronary artery disease treatment

The consistency and quality of the long-term clinical results for the Endeavor® drug-eluting stent (DES) from Medtronic, Inc., continue to distinguish it as a treatment for coronary artery disease, according to newly released data.

16 Mar 2010

Boston Scientific announces results from HORIZONS AMI trial assessing Express bare-metal stent

Boston Scientific Corporation today announced results from an analysis of one-year subset data from the HORIZONS AMI trial assessing the impact of diabetes on clinical and angiographic outcomes in heart attack patients treated with the TAXUS® Express2™ Paclitaxel-Eluting Stent System or the Express® bare-metal stent.

16 Mar 2010

Positive results from second phase of ABSORB clinical trial on BVS technology

Abbott today announced positive 30-day results from the first 101 patients enrolled in the second phase of the ABSORB trial. Patients treated with Abbott's bioresorbable vascular scaffold (BVS), under clinical investigation in Europe, demonstrated no cases of blood clots (thrombosis), no need for repeat procedures (ischemia-driven target lesion revascularization) and a very low rate of major adverse cardiac events (MACE(1) rate of 2.0 percent) at 30 days.

15 Mar 2010

St. Jude Medical to exhibit cardiac clinical solution products portfolio at ACC 2010

St. Jude Medical, Inc. today announced it will display products and technologies from the company’s wide array of clinical solutions in the cardiology, cardiac surgery, atrial fibrillation and cardiac rhythm management markets at ACC 2010.

12 Mar 2010

RMR can non-invasively, quickly and accurately detect presence of sCAD

Newly published data shows using a Respiratory Modulation Response (RMR) is a novel, non-invasive measure to quickly and accurately detect the presence of significant coronary artery disease (sCAD). Patients in the study with sCAD had a lower RMR compared to patients without, regardless of their risk factors or clinical history of angina, previous myocardial infarction (MI), or angioplasty.

3 Mar 2010

InfraReDx to exhibit novel LipiScan Coronary Imaging System at LUMEN 2010

InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased intracoronary tissues, today announced that the Company will be exhibiting at LUMEN 2010, the world's premier ST-elevation myocardial infarction (STEMI) meeting, to be held February 25-27, 2010 at the Loews Miami Beach Hotel in Miami Beach, Florida. The 9th Annual LUMEN meeting is an educational symposium providing updates from world-renowned experts in key areas of interventional cardiology and vascular intervention.

24 Feb 2010

Members of interventional cardiology community wish former President Bill Clinton a quick recovery

Members of the interventional cardiology community wish former President Bill Clinton a quick recovery following his recent hospitalization for angioplasty and stenting.

15 Feb 2010

SMT Research and Development completes first two clinical cases using Shimon Embolic Filter

SMT Research and Development, Ltd., a privately held company, announced that it has completed its first two clinical cases using the Shimon Embolic Filter [SHEF] (TM). SMT R&D developed a novel technology for brain protection (Neuroprotection) from stroke complication hazards arising from invasive cardiology procedures and heart surgery.

10 Feb 2010